Gene therapy for cystic fibrosis utilizing a replication deficient recombinant adenovirus vector to deliver the human cystic fibrosis transmembrane conductance regulator cDNA to the airways. A phase I study. - Suppr | 超能文献

Gene therapy for cystic fibrosis utilizing a replication deficient recombinant adenovirus vector to deliver the human cystic fibrosis transmembrane conductance regulator cDNA to the airways. A phase I study.

出版信息

Hum Gene Ther. 1994 Aug;5(8):1019-57. doi: 10.1089/hum.1994.5.8-1019.

DOI:10.1089/hum.1994.5.8-1019

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Gene therapy for cystic fibrosis utilizing a replication deficient recombinant adenovirus vector to deliver the human cystic fibrosis transmembrane conductance regulator cDNA to the airways. A phase I study.

Hum Gene Ther. 1994 Aug;5(8):1019-57. doi: 10.1089/hum.1994.5.8-1019.

2

Evaluation of repeat administration of a replication deficient, recombinant adenovirus containing the normal cystic fibrosis transmembrane conductance regulator cDNA to the airways of individuals with cystic fibrosis.对携带正常囊性纤维化跨膜传导调节因子cDNA的复制缺陷型重组腺病毒重复给药至囊性纤维化患者气道的评估。

Hum Gene Ther. 1995 May;6(5):667-703. doi: 10.1089/hum.1995.6.5-667.

3

A phase 1 study, in cystic fibrosis patients, of the safety, toxicity, and biological efficacy of a single administration of a replication deficient, recombinant adenovirus carrying the cDNA of the normal cystic fibrosis transmembrane conductance regulator gene in the lung.一项针对囊性纤维化患者的1期研究，旨在评估单次给予一种携带正常囊性纤维化跨膜传导调节因子基因cDNA的复制缺陷型重组腺病毒在肺部的安全性、毒性和生物学疗效。

Hum Gene Ther. 1995 May;6(5):643-66. doi: 10.1089/hum.1995.6.5-643.

4

Adenovirus-mediated gene transfer for cystic fibrosis: Part A. Safety of dose and repeat administration in the nasal epithelium. Part B. Clinical efficacy in the maxillary sinus.腺病毒介导的基因转移治疗囊性纤维化：A部分。鼻上皮中剂量及重复给药的安全性。B部分。上颌窦的临床疗效。

Hum Gene Ther. 1995 Feb;6(2):205-18. doi: 10.1089/hum.1995.6.2-205.

5

Gene therapy of cystic fibrosis lung disease using E1 deleted adenoviruses: a phase I trial.使用E1缺失腺病毒对囊性纤维化肺病进行基因治疗：一项I期试验。

Hum Gene Ther. 1994 Apr;5(4):501-19. doi: 10.1089/hum.1994.5.4-501.

6

Development and analysis of recombinant adenoviruses for gene therapy of cystic fibrosis.用于囊性纤维化基因治疗的重组腺病毒的开发与分析

Hum Gene Ther. 1993 Aug;4(4):461-76. doi: 10.1089/hum.1993.4.4-461.

7

Cystic fibrosis gene therapy using an adenovirus vector: in vivo safety and efficacy in nasal epithelium.使用腺病毒载体的囊性纤维化基因治疗：鼻上皮的体内安全性和有效性

Hum Gene Ther. 1994 Feb;5(2):209-19. doi: 10.1089/hum.1994.5.2-209.

8

Trans-complementation of E1-deleted adenovirus: a new vector to reduce the possibility of codissemination of wild-type and recombinant adenoviruses.E1 缺失腺病毒的转互补作用：一种降低野生型和重组腺病毒共传播可能性的新型载体。

Hum Gene Ther. 1995 Jun;6(6):711-21. doi: 10.1089/hum.1995.6.6-711.

9

In vivo evaluation of the safety of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lung.腺病毒介导的人囊性纤维化跨膜传导调节因子cDNA转导至肺的安全性的体内评估。

Hum Gene Ther. 1994 Jun;5(6):731-44. doi: 10.1089/hum.1994.5.6-731.

10

Acute responses of non-human primates to airway delivery of an adenovirus vector containing the human cystic fibrosis transmembrane conductance regulator cDNA.非人灵长类动物对气道递送含人囊性纤维化跨膜传导调节因子cDNA的腺病毒载体的急性反应。

Hum Gene Ther. 1994 Jul;5(7):821-36. doi: 10.1089/hum.1994.5.7-821.

引用本文的文献

1

Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancer.T细胞受体基因在修饰造血干细胞用于癌症基因治疗方面的潜在应用。

Pathol Oncol Res. 1999;5(1):3-15. doi: 10.1053/paor.1999.0003.

2

The influence of sodium glycocholate and other additives on the in vivo transfection of plasmid DNA in the lungs.甘氨胆酸钠及其他添加剂对肺部质粒DNA体内转染的影响。

Pharm Res. 1996 Feb;13(2):202-9. doi: 10.1023/a:1016078728202.

3

Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy.用于基因治疗的腺病毒载体的浓度及生物活性评估。

J Virol. 1996 Nov;70(11):7498-509. doi: 10.1128/JVI.70.11.7498-7509.1996.